Skip to content
Screener

Glaukos GKOS Total Liabilities & Equity

Total Liabilities & Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$201.06B+4.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$104.87M-14.0%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
Schering-Plough logo
Schering-PloughSGP
$258.39M
Bausch + Lomb logo
Bausch + LombBLCO
$13.86B+0.2%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025--
Common stock, $0.001 par value; 150,000 shares authorized; 58,886 and 57,539 shares issued and 58,858 and 57,511 shares outstanding as of June 30, 2026 and December 31, 2025, respectively5958
Additional paid-in capital1,651,4651,586,056
Accumulated other comprehensive income2,3843,303
Accumulated deficit(971,290)(933,130)
Less treasury stock (28 shares as of June 30, 2026 and December 31, 2025)(132)(132)
Total stockholders' equity682,486656,155
Total liabilities and stockholders' equity$920,521$893,487

Item 1. Financial Statements

FAQ

What is Glaukos's total liabilities & equity?
Glaukos (GKOS) reported total liabilities & equity of $920.52M in Q2 2026.
How has Glaukos's total liabilities & equity changed year-over-year?
Glaukos's total liabilities & equity decreased by 6.7% year-over-year, from $986.96M to $920.52M.
What is the long-term trend for Glaukos's total liabilities & equity?
Over 5 years (2020 to 2025), Glaukos's total liabilities & equity has grown at a -2.3% compound annual growth rate (CAGR), from $1.01B to $893.49M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Glaukos's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude